Lamarca, A. (Angela)

Filtering

2020 - 20232

Settings

Author search.filters.isAuthorOfPublication.472fbaec-84f4-40b6-91f3-6426832d67a0

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022
    (2023) Osterlund, P. (P.); O'Reilly, E.M. (E. M.); Gill, S. (S.); Tabernero, J. (J.); Berlin, J. (J.); Galle, P. (P.); Lordick, F. (F.); Van-Cutsem, E. (E.); Ruiz-Garcia, E. (E.); Cervantes, A. (Andrés); Verslype, C. (Chris); O'Connor, J.M. (J. M.); Wasan, H. (H.); Sangro, B. (Bruno); Bekaii-Saab, T. (T.); Llovet, J.M. (J. M.); Philip, P. (P.); Laurent-Puig, P. (P.); Baere, T. (T.) de; Mukherji, D. (D.); Prager, G. (G.); Haustermans, K. (K.); Ducreux, M. (M.); Macarulla, T. (T.); Eng, C. (C.); Obermannova, R. (R.); Lamarca, A. (Angela); Muro, K. (K.); Seufferlein, T. (T.); Gruenberger, T. (T.); Abou-Alfa, G.K. (Ghassan K.)
    This article summarises expert discussion on the management of patients with hepatocellular carcinoma (HCC), which took place during the 24th World Gastrointestinal Cancer Congress (WGICC) in Barcelona, July 2022. A multidisciplinary approach is mandatory to ensure an optimal diagnosis and staging of HCC, planning of curative and therapeutic options, including surgical, embolisation, ablative strategies, or systemic therapy. Furthermore, in many patients with HCC, underlying liver cirrhosis represents a challenge and influences the therapeutic options.
  • Thumbnail Image
    Current and novel therapeutic opportunities for systemic therapy in biliary cancer
    (Springer Nature, 2020) Banales, J.M. (Jesús M.); Tavolari, S. (Simona); Rodrigues, C.M.P. (Cecilia M. P.); Marzioni, M. (Marco); Fernández-Barrena, M.G. (Maite G.); Mentrast, G. (Giulia); Mertens, J. (Joachim); Rodrigues, P.M. (Pedro M.); Cardinale, V. (Vincenzo); Da-Silva-Ruivo, A. (Ana); La-Casta-Muñoa, A. (Adelaida); Vogel, A. (Arndt); Landa-Magdalena, A. (Ana); Bridgewater, J. (John); Macias, R. (Rocío); Braconi, C. (Chiara); Munoz-Garrido, P. (Patricia); Segatto, O. (Oreste); Valle, J.W. (Juan W.); Lamarca, A. (Angela); Brandi, G. (Giovanni); Marin, J.J.G (Jose J.G.); Acedo, P. (Pilar); Giuseppina-Prete, M. (Maria)
    Biliary tract cancers (BTCs) are a group of rare and aggressive malignancies that arise in the biliary tree within and outside the liver. Beyond surgical resection, which is beneficial for only a small proportion of patients, current strategies for treating patients with BTCs include chemotherapy, as a single agent or combination regimens, in the adjuvant and palliative setting. Increased characterisation of the molecular landscape of these tumours has facilitated the identification of molecular vulnerabilities, such as IDH mutations and FGFR fusions, that can be exploited for the treatment of BTC patients. Beyond targeted therapies, active research avenues explore the development of novel therapeutics that target the crosstalk between cancer and stroma, the cellular pathways involved in the regulation of cell death, the chemoresistance phenotype and the dysregulation of RNA. In this review, we discuss the therapeutic opportunities currently available in the management of BTC patients, and explore the strategies that can support the implementation of precision oncology in BTCs, including novel molecular targets, liquid biopsies and patient-derived predictive tools.